Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals

Grants

Funding Acknowledgements

The study is funded by the National Institutes of Health (N.I.H.), USA R01AI060449. NCHECR is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, The University of New South Wales. Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS) with centers (Principal Investigators) at The Johns Hopkins University Bloomberg School of Public Health (Joseph B. Margolick, Lisa Jacobson), Howard Brown Health Center and Northwestern University Medical School (John Phair), University of California, Los Angeles (Roger Detels), and University of Pittsburgh (Charles Rinaldo). The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute and the National Heart, Lung and Blood Institute. UOI-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-Al-35043, UO1-AI-37984, UO1-Al35039, UO1-AI-35040, UO1-AI-37613, UO1-AI35041. Website located at http://www.statepi.jhsph.edu/inacs/macs.html. The authors wish to acknowledge the study participants and research staff at all sites who contributed to this study. In particular, the authors wish to acknowledge Professor Jenny Hoy from the Alfred Hospital, Melbourne and Dr Robert Finlayson at Taylor Square Private Clinic ill Sydney, who supervised the recruitment and conduct of the study at their respective study sites.